Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multiple Ascending-Dose PK and D2 Occupancy Study of HP-3070 Patch in Schizophrenia
jRCT1080222475Phase 1
- Sponsor
- Hisamitsu Pharmaceutical Co., Inc.
- Start
- Apr 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Secuado in schizophrenia and schizoaffective disorder, sponsored by Hisamitsu Pharmaceutical Co., Inc. Primary endpoints: Pharmacokinetic profile of HP-3070 and Dopamine D2 receptor occupancy.
02
Drugs
Secuado
03
Conditions
schizophreniaschizoaffective disorder
Beyond the preview
Go deeper on jRCT1080222475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080222475.